

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

SB 791

March 7, 2017

SUMMARY OF BILL: Revises which patients qualify to receive a prescription for buprenorphine mono or for buprenorphine without use of naloxone for the treatment of substance use disorder.

ESTIMATED FISCAL IMPACT:

NOT SIGNIFICANT

Assumptions:

- Based on information provided by the Department of Health, the proposed legislation can be accommodated within existing resources without an increased appropriation or reduced reversion.
- The Board of Pharmacy can update any rules during regularly-scheduled board meetings; therefore, any fiscal impact is estimated to be not significant.
- Pursuant to Tenn. Code Ann. § 4-29-121, all health related boards are required to be self-supporting over a two-year period. The Board of Pharmacy had an annual surplus of \$284,085 in FY14-15, an annual surplus of \$885,058 in FY15-16, and a cumulative reserve balance of \$2,236,772 on June 30, 2016.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in blue ink that reads "Krista M. Lee".

Krista M. Lee, Executive Director

/jem